As several therapeutic strategies developed against FSHD focus on DUX4 inhibition our study draws attention to the high sequence identity shared with DUX4C as well as DUX4L26 (DUXO), the latter also detected at low level in skeletal muscle. Here, DUX4L26 is linked to facioscapulohumeral muscular dystrophy.